The aim: To determine the influence of obesity on cutaneous microcirculation in patients with different stages of obesity and without cardio-vascular pathologies. Materials and methods: The 67 eligible patients with obesity were enrolled into the main group in this research. 20 healthy patients with normal body weight were included in the control group in this study. The mean age and gender were similar among the groups. Each patient underwent a clinical evaluation during the consultation, biological tests, electrocardiogram, Laser Doppler flowmetry. Results: There was a significant decrease in IM and σ in patients with class II obesity and class III obesity compared with control group. IV was decreased in all groups, but the significant differences were recorded only among patients with obesity and not among overweight patients. During wavelet analysis a significant decrease of the AmaxE was detected in all 4 groups (by 14,7%, 37,7%, 52,4%, 57,4% respectively, P < 0,05). The most significant changes were recorded in the heart spectrum (AmaxC). Conclusions: Overweight patients and patients with obesity without cardio-vascular pathology have initial manifestations of microcirculatory disorders, which deteriorate with an increase of BMI. Changes in microcirculation in patients with obesity characterized by the significant decrease of microvessels perfusion, decreasing endothelial and increasing heart specter modulations. Only high BMI was found to be associated with impaired microcirculation endothelial function (AmaxE B=0.446, 95% CI [0,15, 0,92]) according to the results of regression analysis.

No abstract

As a skeletal muscle cell-derived protein, Irisin regulates glucose and lipid metabolism, mitochondrial function, myogenesis, switching white adipocytes to brown fat-like cells, and thermogenesis and energy expenditure. The descriptive review aim is to summarize the knowledge regarding irisin as novel molecular mediators of energy metabolism of remote tissue with promising diagnostic and predictive values for CV risk in connection with a presence of metabolic conditions. The following database were used for searching of life science and biomedical information MEDLINE, the Web of Science, Medline (PubMed), the Cochrane Central, and EMBASE English publications to satisfy the keywords of this investigation. Lowered concentrations of irisin were found in the patients with known CV disease including heart failure, Type 2 Diabetes Mellitus (T2DM), but the levels of circulating irisin were increased in obesity and pre-diabetes patients compared to healthy volunteers. In the general population, low levels of irisin have closely predicted T2DM, atherosclerosis, and coronary artery disease. Circulating levels of irisin in patients that have incident Heart Failure (HF) with reduced ejection fraction were related to the severity of the disease and can be a marker of cardiac cachexia. In contrast, in acute HF patients increased the levels of irisin in peripheral blood positively related to a one-year CV mortality rate. Large clinical studies are needed to determ the predictive role of irisin in the natural evolution of CV disease including HF, myocardial infarction, and cardiac cachexia.